Other Events ·
Oncolytics Biotech Inc. announced that the FDA has granted Fast Track designation to pelareorep in combination with a…
ONCYOncolytics Biotech Inc
Oncolytics Biotech Inc. announced that the FDA has granted Fast Track designation to pelareorep in combination with a checkpoint inhibitor for treating inoperable, locally recurrent or metastatic squamous cell carcinoma of the anal canal. This designation facilitates expedited review and more frequent interactions with the FDA. The company is targeting an estimated $1 billion annual U.S. commercial opportunity. Oncolytics Biotech Inc. is a clinical-stage immunotherapy company developing investigational RNA immunotherapeutic agents for gastrointestinal cancers.